Anti-Inflammatory Agents May Have Role in COVID-19 Pneumonia

(MedPageToday) Infliximab and abatacept showed trends for improved outcomes in ACTIV-1 IM trial. Use of the anti-inflammatory agents infliximab (Remicade) and abatacept (Orencia) added to standard of care showed a hint of improvement in outcomes for patients hospitalized with COVID-19 pneumonia, according to results from the ACTIV-1 IM trial. Compared with a median time to recovery of 9 days with placebo, it was 8 days with infliximab (OR 1.13, 95% CI 0.99-1.29, P=0.063) and 9 days with abatacept (OR 1.14, 95% CI 1.00-1.29, P=0.057), reported Emily Ko, MD, PhD, of Duke University Health System in Durham, North Carolina, during her late-breaking presentation at IDWeek.